ERBB2 and breast cancer: Although the immunohistochemical expression of this receptor in CMT has been widely investigated, the results of different studies are conflicting; some authors have not observed HER2 immunoreactivity [16,17], albeit others described variable degrees of immunostaining in mammary tumors in this species [18,19,20,21].